DrugPatentWatch Database Preview
AMERGE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Amerge patents expire, and when can generic versions of Amerge launch?
Amerge is a drug marketed by Glaxosmithkline Llc and is included in one NDA.
The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.
Summary for AMERGE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 70 |
| Clinical Trials: | 4 |
| Patent Applications: | 387 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AMERGE |
| DailyMed Link: | AMERGE at DailyMed |
Pharmacology for AMERGE
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Synonyms for AMERGE
| 10X8X4P12Z |
| 143388-64-1 |
| 1H-Indole -5-ethanesulfonamide,N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride |
| 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride |
| 2-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-ethanesulfonic acid methylamide Hydrochloride |
| 388N641 |
| A808063 |
| AB0033380 |
| ABP001029 |
| AC-5014 |
| AC1L1U3C |
| AC1Q3ETY |
| AK398843 |
| AKOS005145806 |
| Amerge (TN) |
| AN-5269 |
| API0000686 |
| AT-19354 |
| AWEZYKMQFAUBTD-UHFFFAOYSA-N |
| C17H25N3O2S.HCl |
| CAS-143388-64-1 |
| CCG-221770 |
| CHEBI:7479 |
| CHEMBL1200601 |
| CS-2132 |
| CTK8E8530 |
| D00674 |
| DSSTox_CID_28990 |
| DSSTox_GSID_49064 |
| DSSTox_RID_83255 |
| DTXSID6049064 |
| FT-0672649 |
| GG-548 |
| GR 85548A |
| GR-85548A |
| HY-B0197A |
| J-007804 |
| KS-00000OQE |
| LS-172502 |
| MFCD08141821 |
| MLS006010726 |
| MolPort-003-849-333 |
| N-methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonamide hydrochloride |
| N-methyl-2-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]ethanesulfonamide hydrochloride |
| N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]ethanesulfonamide Hydrochloride |
| N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide hydrochloride |
| N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;hydrochloride |
| N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide hydrochloride |
| n-methyl-3-(1-methyl-4-piperidinyl)-1h-indole-5-ethanesulphonamide hydrochloride |
| N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide, hydrochloride |
| N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride |
| Naramig |
| Naratriptan (hydrochloride) |
| Naratriptan HCl |
| NARATRIPTAN HYDROCHLORIDE |
| Naratriptan hydrochloride (JAN/USAN) |
| Naratriptan hydrochloride [USAN:USP] |
| Naratriptan hydrochloride [USAN] |
| Naratriptan hydrochloride, >=98% (HPLC) |
| Naratriptan hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| naratriptanhydrochloride |
| NCGC00181786-01 |
| NCGC00181786-02 |
| NCGC00261151-01 |
| PubChem16865 |
| Q-201448 |
| QCR-255 |
| RB3224 |
| RTC-070946 |
| s1488 |
| SCHEMBL41527 |
| SMR002529694 |
| TC-070946 |
| Tox21_113617 |
| Tox21_113617_1 |
| Tox21_500466 |
| UNII-10X8X4P12Z |
| VA11356 |
| X6918 |
US Patents and Regulatory Information for AMERGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-002 | Feb 10, 1998 | AB | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-001 | Feb 10, 1998 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for AMERGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-002 | Feb 10, 1998 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-001 | Feb 10, 1998 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
